This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

John McDonald
Corporate VP and Global Head Business Development at Novo Nordisk


John McDonald joined Novo Nordisk in October 2018. Prior to Novo John held various roles at Biogen Inc., MPM Capital, Genzyme Corporation, Millennium Pharmaceuticals, and Genentech. In his career, John has led or participated in the evaluating, structuring and negotiating of numerous mergers and acquisitions, licenses and strategic alliances, including Biogen’s collaborations with Sangamo BioSciences, AGTC, Mitsubishi Tanabe, UCB, and Portola Pharmaceuticals, Inc. and Biogen’s acquisition of Stromedix, Inc., Millennium's Ex-U.S. collaboration with Ortho Biotech/Johnson & Johnson for VELCADE, the restructuring of Millennium's relationship with Schering-Plough Corp. for INTEGRILIN, and the sale of Millennium's interest in its CAMPATH joint venture, Genzyme’s alliance with BioMarin for ALDURAZYME, and Genentech’s alliances with Xoma Corporation (RAPTIVA), and IDEC Pharmaceuticals (RITUXAN). John holds a J.D. from the University of California, Hastings College of Law, and an M.B.A., Beta Gamma Sigma, and a B.S., Phi Beta Kappa, from the Haas School of Business, University of California, Berkeley.

Agenda Sessions

  • ADVANCE LIVE SESSION - The pharma perspective: The unintended positive consequences of COVID-19